PRINCETON, N.J., June 29, 2011 /PRNewswire/ --PharmaNet Development Group, Inc., a leading provider of clinical development services to pharmaceutical, biotechnology, generic drug and medical device companies, announced today that Joel Posener, MD, has joined the Company as Executive Medical Director, Neuroscience. Dr. Posener will support PharmaNet project teams conducting clinical trials in psychiatry and neurology, and will provide drug development advice to clients in the area of neuroscience.
“We are thrilled Joel has joined PharmaNet,” said Steven Leventer, PhD, Vice President and General Manager, Neuroscience. “His distinguished medical and clinical credentials will be a valuable addition to PharmaNet’s experienced neuroscience team. Joel’s appointment further demonstrates our commitment to help our clients develop innovative neuroscience therapeutics.”
Dr. Posener obtained his medical degree from McGill University, completed a residency in psychiatry and fellowship in psychiatric research at Harvard Medical School and Massachusetts Mental Health Center, and is board certified in Psychiatry. Prior to joining PharmaNet, Dr. Posener held roles at Wyeth as Senior Director, Neuroscience Medical Research and Senior Director, Early Development and Clinical Pharmacology. He directed Phase II projects in a variety of psychiatric indications including cognitive impairment in schizophrenia, bipolar disorder and depression. Dr. Posener has also managed early clinical development programs in schizophrenia, depression and Alzheimer’s disease.
Before joining the pharmaceutical industry, Dr. Posener served on the faculty of Harvard Medical School and Washington University School of Medicine in St. Louis, where he was also Medical Director of Metropolitan St. Louis Psychiatric Center, an academically affiliated public psychiatric hospital. He has published widely on mood disorders and related pathophysiogic processes. Dr. Posener currently holds an appointment as Clinical Associate Professor of Psychiatry at Temple University School of Medicine.
PharmaNet has conducted more than one hundred neuroscience clinical trials in the past five years. PharmaNet’s success in neuroscience is the result of its therapeutically-aligned approach to serving our clients, in which available and informed senior neuroscience experts are integral members of project teams led by project managers and staffed by monitors with significant neuroscience experience. PharmaNet has conducted studies in virtually every area of psychiatry and neurology, all over the world.
About PharmaNet
PharmaNet Development Group, Inc., a recognized leader of global drug development services to the pharmaceutical, biotechnology, generic drug, and medical device industries, provides comprehensive capabilities in Phase I-IV clinical development, bioanalytical and bioequivalence services, regulatory, staffing, and therapeutic solutions. For the applied knowledge and intelligent solutions needed to accelerate drug development programs of all sizes around the world, PharmaNet works for you. For more information, please visit www.PharmaNet.com.
Contact: Anne-Marie Hess
Phone: (609) 951-6842
E-mail: ahess@pharmanet.com
SOURCE PharmaNet Development Group, Inc.
